Hosted on MSN

VOR shares rally over 40% in pre-market trade after JPMorgan initiates bullish coverage

・Vor Biopharma shares surged over 40%after JPMorgan initiated coverage of the company. ・JPMorgan’s bullish stance comes amid Phase 3 clinical trial success for an autoimmune drug, telitacicept. ・On ...
Yahoo Finance

Vor Biopharma (VOR): Valuation Check After Positive Telitacicept Phase 3 Data and Upbeat JPMorgan Coverage

Vor Biopharma (VOR) has jumped onto investors’ radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that frames the drug’s long term ...
Nasdaq

JP Morgan Initiates Coverage of Vor Biopharma (VOR) with Overweight Recommendation

Fintel reports that on December 9, 2025, JP Morgan initiated coverage of Vor Biopharma (NasdaqGS:VOR) with a Overweight recommendation. As of December 6, 2025, the average one-year price target for ...
Nasdaq

TD Cowen Initiates Coverage of Vor Biopharma (VOR) with Buy Recommendation

Fintel reports that on December 17, 2025, TD Cowen initiated coverage of Vor Biopharma (NasdaqGS:VOR) with a Buy recommendation. As of December 6, 2025, the average one-year price target for Vor ...